GB
Gennady Bratslavsky

Elite Scholar

572
Works
10,006
Citations
55
H-Index
Search Authors
Author Statistics
External Links
OpenAlex Profile ORCID Profile

Gennady Bratslavsky

Also known as: Bratslavsky Gennady, Bratslavsky, Gennady, G Bratslavsky, G. Bratslavsky, GENNADY BRATSLAVSKY

572

Total Works

10,006

Citations

55

H-Index

170

i10-Index

Citation & Works Trend by Year
29 years active
Top Research Topics
Renal cell carcinoma treatment (236) Bladder and Urothelial Cancer Treatments (187) Cancer Genomics and Diagnostics (124) Adrenal and Paraganglionic Tumors (115) Prostate Cancer Treatment and Research (107)
Recent Publications
15 shown
Year Publication Title Citations Action
2026 Can Clinico-Genomic Characterization with the Prolaris Test Reveal More Aggressive Prostate Cancer among Patients with Lower Gleason Grade Groups? Research Square 0
2026 Genomic landscape of TP53 Y220C–mutated clinically advanced prostate carcinoma (CAPC) International Journal of Cancer Care and Delivery 0
2026 Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine Oncotarget 0
2026 Supplementary Table S4 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Supplementary Table S11 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Supplementary Table S10 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Supplementary Table S6 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Supplementary Table S7 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Figure 1 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Table 2 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Supplementary Table S8 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Table 3 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Supplementary Table S2 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Supplementary Figure S1 from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0
2026 Data from 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study 0

Data source: OpenAlex API